Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report

Table 1 Reported cases of allergic bronchopulmonary aspergillosis treated with dupilumab

Ref.	Age, yr	Sex	Timing of dupilumab therapy	Treatment in combination with dupilumab	Baseline IgE (IU/mL)	Baseline eosinophil count (/µL)	Chest CT findings
Ramonell et al[10], 2020	60	Female	Disease recurrence	OCS	561	90	Cylindrical bronchiectasis
Ramonell et al[10], 2020	51	Female	Disease recurrence	OCS	> 2000	90	Bilateral central bronchiectasis
Ramonell et al[10], 2020	33	Male	Disease diagnosis	Voriconazole	11290	1750	Mild diffuse bronchiectasis
Mümmler et al[5], 2020	49	Female	Disease recurrence	OCS	7000	950	Pulmonary infiltrates, diffuse pulmonary bronchiectasis and bronchial wall thickening
Tashiro et al[11], 2021	72	Female	Disease diagnosis	None	2525	5637	Centrilobular nodules, infiltrations, and high-attenuation mucus in the bronchi with central dilatation
Mikura et al[9], 2021	45	Male	Disease recurrence	OCS, itraconazole	2306	1914	High-attenuation mucus and ground glass opacity
Present case	54	Female	Disease recurrence	OCS, itraconazole	2833	1180	Consolidation, ground-glass opacity, and high-attenuation mucus

IgE: Immunoglobulin E; CT: Computed tomography; OCS: Oral corticosteroids.